Abstracts tagged "complement"

Abstract Number: 0924 • ACR Convergence 2023
Distinct Cell-Bound Complement Activation Products Associate with Disease Activity and Immune Transcriptional Signatures in SLE
Gabriel Arguelles, Lynne Mitchell, Dennis Hourcade, John Atkinson, Elisha Roberson and Alfred Kim, Washington University School of Medicine, St. Louis, MO
Background/Purpose: Complement plays a central role in SLE, generating an array of bioactive soluble and cell-bound complement activation products (CB-CAPs) during disease activity. Data are…
Abstract Number: 0562 • ACR Convergence 2023
HDL-Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus
Ivan Ferraz Amaro¹, Maria García-González¹, Fuensanta Gómez-Bernal¹, Juan Carlos Quevedo-Abeledo², Yolanda Fernández-Cladera¹, Agustín F González-Rivero¹ and Miguel A Gonzalez-Gay³, ¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, ³IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL) cholesterol to accept cholesterol from macrophages, has been linked to cardiovascular events. Systemic lupus…
Abstract Number: 1591 • ACR Convergence 2023
Complement Factor D/Adipsin Knockout Mice Demonstrate Disparate Pain and Structural Damage Phenotypes in Obesity-induced Post Traumatic Osteoarthritis
Kelsey Collins¹, Kristin Lenz², Arin Oestreich², Luke Springer², Antonina Akk², Huimin Yan², Xiaobo Wu², John Atkinson³, Christine Pham⁴ and Farshid Guilak⁴, ¹University of California San Francisco, San Francisco, CA, ²Washington University in St. Louis, St. Louis, MO, ³Washington University School of Medicine, St. Louis, MO, ⁴Washington University, St. Louis, MO
Background/Purpose: Osteoarthritis (OA) is the leading cause of musculoskeletal pain, which is a primary driver of care-seeking behavior. There is lack of mechanistic information detailing…
Abstract Number: 0565 • ACR Convergence 2023
Insulin Resistance and the Complement System Are Linked in Patients with Systemic Lupus Erythematosus
José María Viotti-Serra¹, Maria García-González¹, Fuensanta Gómez-Bernal¹, Juan Carlos Quevedo-Abeledo², Yolanda Fernández-Cladera¹, Agustín F González-Rivero¹, Miguel A Gonzalez-Gay³ and Ivan Ferraz Amaro¹, ¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, ³IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) patients more commonly have insulin resistance (IR) than control subjects. Recent studies have revealed that the complement (C) system is…
Abstract Number: 1605 • ACR Convergence 2023
Complement Activation as a Marker of Thrombosis Risk in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Cecile Yelnik¹, Shruti Chaturvedi², Julien Labreuche¹, Xiang-Zuo Pan³, H Michael Belmont⁴, Kello Nina⁵, Paul R. Fortin⁶, D. Ware Branch⁷, Yu Zuo⁸, Rohan Willis⁹, Robert Brodsky¹⁰, Jane Salmon¹¹, Maria Laura Bertolaccini¹², Hannah Cohen¹³, Michelle Petri¹⁴, Doruk Erkan¹¹ and On Behalf Of APS ACTION¹⁵, ¹University of Lille, Lille, France, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³John Hopkins University, Baltimore, MD, ⁴NYU School of Medicine, New York, NY, ⁵Northwell Health, Brooklyn, NY, ⁶Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ⁷University of Utah, Salt Lake City, UT, ⁸University of Michigan, Ann Arbor, MI, ⁹University of Texas Medical Branch, Galveston, TX, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Hospital for Special Surgery, New York, NY, ¹²King's College London, London, United Kingdom, ¹³University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ¹⁵on behalf of APS ACTION, New York, NY
Background/Purpose: Recent studies implicate complement activation in the pathophysiology of antiphospholipid syndrome (APS), especially in patients with severe manifestations, such as catastrophic APS (CAPS). This…
Abstract Number: 0576 • ACR Convergence 2023
Enhancing Systemic Lupus Erythematosus Diagnosis: Comparative Performance Characteristics of TC4d and Anti-T-Cell Antibodies with Conventional Biomarkers
Andrew Concoff¹, Vasileios Kyttaris², Vaneet Sandhu³, Tyler O'Malley⁴, Giorgio Casaburi⁴, Sudha Kumar⁴, Chau Ching Liu⁵, Susan Manzi⁶ and Joeseph Ahearn⁵, ¹Exagen, Los Angeles, CA, ²BIDMC, Boston, MA, ³Loma Linda University, Loma Linda, CA, ⁴Exagen, Vista, CA, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease, affecting multiple organ systems with varying severity among patients. SLE presents a diagnostic challenge…
Abstract Number: 2273 • ACR Convergence 2023
Predicting SLE Disease Activity with Blood Biomarkers: A Step Towards Precision Medicine
Vasileios Kyttaris¹, Tyler O'Malley², Giorgio Casaburi², Sudha Kumar² and Andrew Concoff³, ¹BIDMC, Boston, MA, ²Exagen, Vista, CA, ³Exagen, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is the prototypical autoimmune disease with diverse clinical manifestations and variable treatment response. Conventional biomarkers of SLE activityprovide modest correlation…
Abstract Number: 0960 • ACR Convergence 2022
Serum C3 Level and Glucocorticoid Dose Are Risk Factors for Preterm Birth in Patients with Systemic Lupus Erythematosus
Hiromi Shimada¹, Risa Wakiya¹, shusaku nakashima², Mikiya Kato¹, taichi miyagi³, Yusuke Ushio⁴, Koichi Sugihara⁵, Rina Mino⁶, mao mizusaki⁶, Kanako Chujo⁷, Tomohiro Kameda¹ and Hiroaki Dobashi⁸, ¹Kagawa University, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ³Kagawa University, Kidagun, Japan, ⁴Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ⁵Kagawa University, Miki-cho, Kita-gun, Japan, ⁶Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, ⁷Kagawa University, Miki, Kita District, Kagawa, Japan, ⁸Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Kagawa, Japan
Background/Purpose: Women with Systemic lupus erythematosus (SLE) have more difficulty in achieving a successful pregnancy than healthy women, because of higher risks for adverse pregnancy…
Abstract Number: 1054 • ACR Convergence 2022
Distinct Differences in Complement Perturbation Between Scleroderma-related Interstitial Lung Disease with and Without Emphysema
Claire Beesley¹, Alice Cole², Nina Goldman¹, Odewale Oluwakorede¹, Joseph Barnett², David Abraham¹, Chris Denton¹, Rizgar Mageed³ and Voon Ong⁴, ¹University College London, London, United Kingdom, ²Royal Free Hospital, London, United Kingdom, ³Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom, ⁴UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose: Aberrant complement activation is associated with autoimmune diseases including systemic sclerosis (SSc). As a leading cause of death in SSc, interstitial lung disease (ILD)…
Abstract Number: 1077 • ACR Convergence 2022
Safety of Avacopan in ANCA-Associated Vasculitis: Combined Data from Three Clinical Trials
Pirow Bekker¹, Peter Merkel² and David Jayne³, ¹ChemoCentryx, San Juan Capistrano, CA, ²U of Pennsylvania, Philadelphia, PA, ³University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Avacopan is approved as adjunctive treatment for adults with ANCA-associated vasculitis (AAV). This study aimed to combine and report on data of the safety…
Abstract Number: 1088 • ACR Convergence 2022
Longitudinal Pattern of Circulating Complement Activation in ANCA Vasculitis
Eveline Wu¹, Elizabeth McInnis², Sarah Lewis², Mary Collie², Lauren Blazek², Kristin Kennedy², Yichun Hu², Susan Hogan², Candace Henderson², Caroline Poulton², Dhruti Chen², Vimal Derebail², J Charles Jennette³, Ronald Falk² and Donna Bunch², ¹University of North Carolina, Chapel Hill, NC, ²UNC Kidney Center, The University of North Carolina Chapel Hill, Chapel Hill, NC, ³Department of Pathology and Laboratory Medicine, The University of North Carolina Chapel Hill, Chapel Hill, NC
Background/Purpose: Evidence is accumulating that alternative complement pathway activation is important in ANCA vasculitis pathogenesis. Our group was the first to show that complement activation…
Abstract Number: 1135 • ACR Convergence 2022
Urine Proteomics Implicate Complement C3 and Factor I in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy
Shudan Wang¹, Anna Broder², Daming Shao³, Vartika Kesarwani⁴, Brianna Lally⁵, Masako Suzuki⁶, J. Michelle Kahlenberg⁷, Jennifer Aguilan⁶ and Simone Sidoli⁶, ¹Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, ²Hackensack University Medical Center, Hackensack, NJ, ³Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ⁴University of Connecticut, Farmington, CT, ⁵University of Wisconsin Hospitals and Clinics, Madison, WI, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷University of Michigan, Ann Arbor, MI
Background/Purpose: The complement system has an important and underrecognized role in mediating tubulointerstitial disease in lupus nephritis (LN). The omics big data allows for identifying…
Abstract Number: 1442 • ACR Convergence 2022
Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus
Anca Askanase¹, John Conklin², Michelle Petri³, Vasileios Kyttaris⁴, Yevgeniya Gartshteyn⁵, Wei Tang¹, Anja Kammesheidt⁶ and Roberta Alexander², ¹Columbia University Medical Center, New York, NY, ²Exagen, Inc., Vista, CA, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Columbia University Medical Center, Glen Rock, NJ, ⁶self, Laguna Beach, CA
Background/Purpose: Platelet-bound complement activation products (PC4d) are associated with a history of thrombosis in systemic lupus erythematosus (SLE) (Gartshteyn al., 2021; Petri et al., 2017).…
Abstract Number: 1697 • ACR Convergence 2022
Measurements of Specific Activation Through the Lectin -or Classical Pathway of Complement in Patients with SLE
Anne Troldborg¹, Mads Lamm Larsen¹, Erik J.M. Toonen², Lisa Hurler³, Zoltan Prohaszka³, László Cervenak³, Annette Gudmann Hansen⁴ and Steffen Thiel⁴, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Hycult Biotech, Arnhem-Nijmegen, Netherlands, ³Semmelweis University, Budapest, Hungary, ⁴Aarhus University, Aarhus, Denmark
Background/Purpose: In systemic lupus erythematosus (SLE), the complement system is activated and commonly thought to occur through the classical pathway (CP) [1]. However, our previous…
Abstract Number: 1733 • ACR Convergence 2022
Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium
Anna Jonsson¹, Carlos Donado², Emma Gomez-Rivas¹ and Michael Brenner³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: T cells are major drivers of rheumatoid arthritis (RA) pathogenesis. Most research has focused on CD4 T cells, but we have found that CD8+…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].